{"id":263787,"date":"2026-09-23T11:30:28","date_gmt":"2026-09-23T06:00:28","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=263787"},"modified":"2026-09-23T11:30:28","modified_gmt":"2026-09-23T06:00:28","slug":"glenmark-pharmaceuticals-stock-signals-investors-are-watching","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/","title":{"rendered":"Glenmark Pharmaceuticals: 7 Stock Signals Investors Are Watching Right Now"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Glenmark Pharmaceuticals CMP Rs 2,471.20. 52W range Rs 1,792.60-2,537.60. Mcap Rs 69,512 crore. PE 38.67 vs sector 38.56.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Glenmark Pharmaceuticals stock signals right now span an earnings picture, a shareholding pattern where promoter holding promoter and institutional shareholding figures were not available from the data source used here; investors can check the company&#8217;s latest exchange filing directly, and a technical setup where the stock trades well off its 52-week low of Rs 1,792.60. Debt to equity stands at 0.06, and valuation sits at a P\/E of 38.67 against a sector average of 38.56. Corporate developments in the pharmaceutical formulations and drug discovery space add further context investors are tracking alongside these numbers. None of the seven signals here amounts to a buy or sell call on its own.<\/p>\n<\/p><\/div>\n<p>Glenmark Pharmaceuticals stock signals are unusually layered right now, with the company trading at Rs 2,471.20, 2.6% below its 52-week high of Rs 2,537.60 and 37.9% above its 52-week low of Rs 1,792.60. Glenmark Pharmaceuticals is a well tracked name in the pharmaceutical formulations and drug discovery space, and no single headline captures where the stock stands today.<\/p>\n<p>This article does not make a buy, hold or sell call on Glenmark Pharmaceuticals. It lays out seven signals investors commonly watch, each sourced from the company&#8217;s latest exchange disclosures and financial statements, so readers can form their own view of what is currently working for the stock and what still needs to be watched.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=glenmark-pharmaceuticals-stock-signals-investors-are-watching\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#Glenmark_Pharmaceuticals_Stock_at_a_Glance\" title=\"Glenmark Pharmaceuticals Stock at a Glance\">Glenmark Pharmaceuticals Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#1_Earnings_Trend_at_Glenmark_Pharmaceuticals\" title=\"1. Earnings Trend at Glenmark Pharmaceuticals\">1. Earnings Trend at Glenmark Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#2_FII_Holding_in_Glenmark_Pharmaceuticals\" title=\"2. FII Holding in Glenmark Pharmaceuticals\">2. FII Holding in Glenmark Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#3_Promoter_Holding_in_Glenmark_Pharmaceuticals\" title=\"3. Promoter Holding in Glenmark Pharmaceuticals\">3. Promoter Holding in Glenmark Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#4_Debt_Position_at_Glenmark_Pharmaceuticals\" title=\"4. Debt Position at Glenmark Pharmaceuticals\">4. Debt Position at Glenmark Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#5_Valuation_of_Glenmark_Pharmaceuticals_Shares\" title=\"5. Valuation of Glenmark Pharmaceuticals Shares\">5. Valuation of Glenmark Pharmaceuticals Shares<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#6_Technical_Trend_on_the_Glenmark_Pharmaceuticals_Chart\" title=\"6. Technical Trend on the Glenmark Pharmaceuticals Chart\">6. Technical Trend on the Glenmark Pharmaceuticals Chart<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#7_Corporate_Developments_at_Glenmark_Pharmaceuticals\" title=\"7. Corporate Developments at Glenmark Pharmaceuticals\">7. Corporate Developments at Glenmark Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#What_These_Glenmark_Pharmaceuticals_stock_signals_Mean_Together\" title=\"What These Glenmark Pharmaceuticals stock signals Mean Together\">What These Glenmark Pharmaceuticals stock signals Mean Together<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#FAQs_on_Glenmark_Pharmaceuticals_Stock_Signals\" title=\"FAQs on Glenmark Pharmaceuticals Stock Signals\">FAQs on Glenmark Pharmaceuticals Stock Signals<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#Why_is_Glenmark_Pharmaceuticals_share_price_where_it_is_right_now\" title=\"Why is Glenmark Pharmaceuticals share price where it is right now?\">Why is Glenmark Pharmaceuticals share price where it is right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#What_is_Glenmark_Pharmaceuticalss_current_FII_holding\" title=\"What is Glenmark Pharmaceuticals&#8217;s current FII holding?\">What is Glenmark Pharmaceuticals&#8217;s current FII holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#Is_Glenmark_Pharmaceuticalss_debt_position_a_concern_right_now\" title=\"Is Glenmark Pharmaceuticals&#8217;s debt position a concern right now?\">Is Glenmark Pharmaceuticals&#8217;s debt position a concern right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#What_is_the_promoter_holding_in_Glenmark_Pharmaceuticals\" title=\"What is the promoter holding in Glenmark Pharmaceuticals?\">What is the promoter holding in Glenmark Pharmaceuticals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#Is_Glenmark_Pharmaceuticals_expensive_compared_to_its_sector\" title=\"Is Glenmark Pharmaceuticals expensive compared to its sector?\">Is Glenmark Pharmaceuticals expensive compared to its sector?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#What_recent_corporate_developments_are_relevant_to_Glenmark_Pharmaceuticals\" title=\"What recent corporate developments are relevant to Glenmark Pharmaceuticals?\">What recent corporate developments are relevant to Glenmark Pharmaceuticals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#What_do_the_technical_charts_suggest_about_Glenmark_Pharmaceuticals_right_now\" title=\"What do the technical charts suggest about Glenmark Pharmaceuticals right now?\">What do the technical charts suggest about Glenmark Pharmaceuticals right now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-stock-signals-investors-are-watching\/#Should_investors_buy_Glenmark_Pharmaceuticals_shares_at_current_levels\" title=\"Should investors buy Glenmark Pharmaceuticals shares at current levels?\">Should investors buy Glenmark Pharmaceuticals shares at current levels?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Glenmark_Pharmaceuticals_Stock_at_a_Glance\"><\/span><strong>Glenmark Pharmaceuticals Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Before going through each of the seven Glenmark Pharmaceuticals stock signals in detail, the snapshot below sets the starting point on price, valuation and balance sheet strength.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\">\n<tr>\n<th style=\"text-align:left;border-bottom:1px solid #ddd;padding:6px;\">Metric<\/th>\n<th style=\"text-align:left;border-bottom:1px solid #ddd;padding:6px;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\"><a href=\"https:\/\/univest.in\/stocks\/glenmark\/glenmark-pharmaceuticals-ltd-share-price-today\">Glenmark Pharmaceuticals<\/a> CMP<\/td>\n<td style=\"padding:6px;\">Rs 2,471.20 (NSE, 23 Sep 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">52-Week High<\/td>\n<td style=\"padding:6px;\">Rs 2,537.60 (24 August 2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">52-Week Low<\/td>\n<td style=\"padding:6px;\">Rs 1,792.60 (27 October 2025)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">Market Capitalisation<\/td>\n<td style=\"padding:6px;\">Rs 69,512 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">P\/E Ratio<\/td>\n<td style=\"padding:6px;\">38.67 (Sector P\/E 38.56)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">P\/B Ratio<\/td>\n<td style=\"padding:6px;\">6.61<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">Debt to Equity<\/td>\n<td style=\"padding:6px;\">0.06<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:6px;\">Return on Equity<\/td>\n<td style=\"padding:6px;\">28.08%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"1_Earnings_Trend_at_Glenmark_Pharmaceuticals\"><\/span><strong>1. Earnings Trend at Glenmark Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Glenmark Pharmaceuticals posted trailing-twelve-month revenue of Rs 18,236 crore versus Rs 17,443 crore a year earlier, while net profit moved to Rs 1,798 crore from Rs 1,362 crore, a change of 32.0% on the year. The most recent quarter added Rs 4,084.24 crore in revenue, a change of 24.1% year on year, against Rs 482.83 crore in net profit versus Rs 46.97 crore a year earlier.<\/p>\n<p>net profit jumped sharply year on year in the June 2026 quarter off a weak year-ago base, extending trailing-twelve-month growth of close to 32%. This is the first of the seven Glenmark Pharmaceuticals stock signals worth tracking closely into the next results.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"2_FII_Holding_in_Glenmark_Pharmaceuticals\"><\/span><strong>2. FII Holding in Glenmark Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A full quarterly FII holding series was not available from the data source used here for Glenmark Pharmaceuticals. Where that is the case, the most reliable next step is to check the company&#8217;s latest exchange filing directly, since a single-quarter snapshot can be misleading without the trend around it.<\/p>\n<p>This is worth revisiting once the next quarterly shareholding disclosure is filed.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"3_Promoter_Holding_in_Glenmark_Pharmaceuticals\"><\/span><strong>3. Promoter Holding in Glenmark Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Promoter holding in Glenmark Pharmaceuticals promoter and institutional shareholding figures were not available from the data source used here; investors can check the company&#8217;s latest exchange filing directly.<\/p>\n<p>This is worth revisiting once the next quarterly shareholding disclosure is filed, to see whether the level and direction of change persists.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"4_Debt_Position_at_Glenmark_Pharmaceuticals\"><\/span><strong>4. Debt Position at Glenmark Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Glenmark Pharmaceuticals&#8217;s debt to equity ratio stands at 0.06, one of the balance sheet metrics worth tracking alongside the earnings trend above. A lower or stable ratio generally gives more room to fund growth without leaning further on external borrowing, while a rising one is worth watching for its effect on finance costs.<\/p>\n<p>This debt signal should be read alongside the valuation and corporate development signals below rather than in isolation, since capital raising plans can shift the picture from one quarter to the next.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Valuation_of_Glenmark_Pharmaceuticals_Shares\"><\/span><strong>5. Valuation of Glenmark Pharmaceuticals Shares<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At the current price, Glenmark Pharmaceuticals trades at a price to earnings ratio of 38.67, a premium of close to 0.3% versus the sector average of 38.56. The price to book ratio stands at 6.61.<\/p>\n<p>Whether that premium looks justified depends on the earnings trend from Signal 1 continuing, and it is one of the clearer places where the seven signals can pull in different directions at the same time.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"6_Technical_Trend_on_the_Glenmark_Pharmaceuticals_Chart\"><\/span><strong>6. Technical Trend on the Glenmark Pharmaceuticals Chart<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The stock last traded around Rs 2,471.20, above its short-term average of about Rs 2,463.77, pointing to near-term strength. The 14-day RSI reads close to 42, in neutral territory. The MACD line sits below its signal line, a bearish momentum bias.<\/p>\n<p>Over the past year the stock is currently 2.6% below its 52-week high of Rs 2,537.60 and 37.9% above its 52-week low of Rs 1,792.60. A sustained move back above its recent average would be an early technical sign of stabilisation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"7_Corporate_Developments_at_Glenmark_Pharmaceuticals\"><\/span><strong>7. Corporate Developments at Glenmark Pharmaceuticals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Glenmark Pharmaceuticals is actively involved in discovery of new molecules, both new chemical entities and new biological entities, and posted a net profit that jumped over 6,000% year on year in the March 2026 quarter off a low base tied to one-off items in the prior year.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live fundamentals<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_These_Glenmark_Pharmaceuticals_stock_signals_Mean_Together\"><\/span><strong>What These Glenmark Pharmaceuticals stock signals Mean Together<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>None of these seven signals on its own settles the debate on Glenmark Pharmaceuticals. Reading them as a set, rather than picking out any single one, is the more balanced way to approach the stock right now. The earnings trend, shareholding pattern, balance sheet position, valuation, technical setup and corporate developments each add one piece of the picture, and they do not all point the same way at the same time.<\/p>\n<p>Investors weighing Glenmark Pharmaceuticals would do well to watch the next quarterly results for a read on where margins and profit are heading, alongside the next shareholding pattern update for any shift in institutional positioning. Reading these Glenmark Pharmaceuticals stock signals together, rather than in isolation, remains the more balanced approach. As with any single stock, price movements can be volatile and past trends do not guarantee future performance.<\/p>\n<p>For context, investors following Glenmark Pharmaceuticals often look at how the stock has moved through previous earnings cycles, how peer companies in the same space have reacted to similar corporate developments, and whether broader market conditions such as interest rate moves, sector-wide policy shifts or commodity price swings have played a larger role than company-specific news. None of these broader factors replace the seven signals above, but they help explain why a stock can move sharply even when no single company-specific trigger is visible in the data. Reading a stock&#8217;s price action purely in isolation, without this wider lens, can lead to drawing conclusions that do not hold up once the next quarter&#8217;s numbers or the next shareholding disclosure comes in. Investors are generally better served treating each of these seven factors as one input among several, updated on a rolling basis as new disclosures arrive, rather than as a one-time checklist filled in once and then set aside for the rest of the year without a further look.<\/p>\n<p style=\"margin-top:24px;\"><em>Also Read: <a href=\"https:\/\/univest.in\/blogs\/hdfc-bank-stock-signals-investors-are-watching\/\">HDFC Bank: 7 Stock Signals Investors Are Watching Right Now<\/a><\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Glenmark Pharmaceuticals currently sits at the intersection of several moving parts, from earnings and shareholding to valuation and chart trend, and that is exactly what the seven signals above are meant to surface. This article does not recommend buying, holding or selling Glenmark Pharmaceuticals shares, and readers should form their own view based on their own research and risk appetite.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Glenmark Pharmaceuticals live price and more such signal based stock research.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information and the company&#8217;s exchange filings. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Glenmark_Pharmaceuticals_Stock_Signals\"><\/span><strong>FAQs on Glenmark Pharmaceuticals Stock Signals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Glenmark_Pharmaceuticals_share_price_where_it_is_right_now\"><\/span><strong>Why is Glenmark Pharmaceuticals share price where it is right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Glenmark Pharmaceuticals shares are trading 2.6% below their 52-week high of Rs 2,537.60 and 37.9% above their 52-week low of Rs 1,792.60, shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Glenmark_Pharmaceuticalss_current_FII_holding\"><\/span><strong>What is Glenmark Pharmaceuticals&#8217;s current FII holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> A full quarterly FII holding series was not available for this article; check the company&#8217;s latest exchange filing directly.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Glenmark_Pharmaceuticalss_debt_position_a_concern_right_now\"><\/span><strong>Is Glenmark Pharmaceuticals&#8217;s debt position a concern right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The debt to equity ratio stands at 0.06.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_promoter_holding_in_Glenmark_Pharmaceuticals\"><\/span><strong>What is the promoter holding in Glenmark Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> promoter and institutional shareholding figures were not available from the data source used here; investors can check the company&#8217;s latest exchange filing directly.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Glenmark_Pharmaceuticals_expensive_compared_to_its_sector\"><\/span><strong>Is Glenmark Pharmaceuticals expensive compared to its sector?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Glenmark Pharmaceuticals trades at a price to earnings ratio of 38.67 against a sector average of 38.56.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_recent_corporate_developments_are_relevant_to_Glenmark_Pharmaceuticals\"><\/span><strong>What recent corporate developments are relevant to Glenmark Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Glenmark Pharmaceuticals is actively involved in discovery of new molecules, both new chemical entities and new biological entities, and posted a net profit that jumped over 6,000% year on year in the March 2026 quarter off a low base tied to one-off items in the prior year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_do_the_technical_charts_suggest_about_Glenmark_Pharmaceuticals_right_now\"><\/span><strong>What do the technical charts suggest about Glenmark Pharmaceuticals right now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The stock is trading above its short-term average of about Rs 2,463.77, pointing to near-term strength, with its MACD line below its signal line, a bearish momentum bias.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_investors_buy_Glenmark_Pharmaceuticals_shares_at_current_levels\"><\/span><strong>Should investors buy Glenmark Pharmaceuticals shares at current levels?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This article does not offer a buy, hold or sell recommendation. It lays out seven Glenmark Pharmaceuticals stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why is Glenmark Pharmaceuticals share price where it is right now?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Glenmark Pharmaceuticals shares are trading 2.6% below their 52-week high of Rs 2,537.60 and 37.9% above their 52-week low of Rs 1,792.60, shaped by the earnings trend, shareholding shifts and technical setup covered in this article, rather than any single factor.\"}},{\"@type\":\"Question\",\"name\":\"What is Glenmark Pharmaceuticals's current FII holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"A full quarterly FII holding series was not available for this article; check the company's latest exchange filing directly.\"}},{\"@type\":\"Question\",\"name\":\"Is Glenmark Pharmaceuticals's debt position a concern right now?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The debt to equity ratio stands at 0.06.\"}},{\"@type\":\"Question\",\"name\":\"What is the promoter holding in Glenmark Pharmaceuticals?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"promoter and institutional shareholding figures were not available from the data source used here; investors can check the company's latest exchange filing directly.\"}},{\"@type\":\"Question\",\"name\":\"Is Glenmark Pharmaceuticals expensive compared to its sector?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Glenmark Pharmaceuticals trades at a price to earnings ratio of 38.67 against a sector average of 38.56.\"}},{\"@type\":\"Question\",\"name\":\"What recent corporate developments are relevant to Glenmark Pharmaceuticals?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Glenmark Pharmaceuticals is actively involved in discovery of new molecules, both new chemical entities and new biological entities, and posted a net profit that jumped over 6,000% year on year in the March 2026 quarter off a low base tied to one-off items in the prior year.\"}},{\"@type\":\"Question\",\"name\":\"What do the technical charts suggest about Glenmark Pharmaceuticals right now?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock is trading above its short-term average of about Rs 2,463.77, pointing to near-term strength, with its MACD line below its signal line, a bearish momentum bias.\"}},{\"@type\":\"Question\",\"name\":\"Should investors buy Glenmark Pharmaceuticals shares at current levels?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This article does not offer a buy, hold or sell recommendation. It lays out seven Glenmark Pharmaceuticals stock signals, earnings, FII holding, promoter holding, debt, valuation, technicals and corporate developments, so investors can weigh each signal and form their own view based on their goals and risk appetite.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Glenmark Pharmaceuticals stock signals right now: earnings, FII holding, promoter stake, debt, valuation, technical trend and corporate developments, all in one place, with no buy or sell call.<\/p>\n","protected":false},"author":29,"featured_media":263786,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1007,1019],"class_list":["post-263787","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-pharma-stocks","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["263786"],"rank_math_title":["Glenmark Pharmaceuticals Stock Signals to Watch This Week"],"rank_math_description":["Earnings, FII holding, promoter stake, debt, valuation, technicals and corporate developments now shaping Glenmark Pharmaceuticals stock signals for investors."],"rank_math_focus_keyword":["Glenmark Pharmaceuticals stock signals"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/glenmark-pharmaceuticals-7-stock-signals-investors-are-watching-right-now.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/263787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=263787"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/263787\/revisions"}],"predecessor-version":[{"id":263788,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/263787\/revisions\/263788"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/263786"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=263787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=263787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=263787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}